181 related articles for article (PubMed ID: 32763067)
1. Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices.
Wong W; Wu N; Gupta R; Mansfield AS
Clin Lung Cancer; 2021 May; 22(3):e470-e480. PubMed ID: 32763067
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
Waterhouse D; Iadeluca L; Sura S; Wilner K; Emir B; Krulewicz S; Espirito J; Bartolome L
Target Oncol; 2022 Jan; 17(1):25-33. PubMed ID: 34964940
[TBL] [Abstract][Full Text] [Related]
3. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.
Pavlakis N; Cooper C; John T; Kao S; Klebe S; Lee CK; Leong T; Millward M; O'Byrne K; Russell PA; Solomon B; Cooper WA; Fox S
Pathology; 2019 Dec; 51(7):673-680. PubMed ID: 31668406
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
Rojo F; Conde E; Torres H; Cabezón-Gutiérrez L; Bautista D; Ramos I; Carcedo D; Arrabal N; García JF; Galán R; Nadal E
BMC Cancer; 2022 Mar; 22(1):292. PubMed ID: 35303812
[TBL] [Abstract][Full Text] [Related]
5. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
6. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
7. Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
Bubendorf L; Büttner R; Al-Dayel F; Dietel M; Elmberger G; Kerr K; López-Ríos F; Marchetti A; Öz B; Pauwels P; Penault-Llorca F; Rossi G; Ryška A; Thunnissen E
Virchows Arch; 2016 Nov; 469(5):489-503. PubMed ID: 27535289
[TBL] [Abstract][Full Text] [Related]
8. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
Paz-Ares L; Gondos A; Saldana D; Thomas M; Mascaux C; Bubendorf L; Barlesi F
Lung Cancer; 2022 May; 167():41-48. PubMed ID: 35397297
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
Song Z; Yu X; Zhang Y
Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
[TBL] [Abstract][Full Text] [Related]
10. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
12. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
13. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
Sireci AN; Krein PM; Hess LM; Khan T; Willey J; Ayars M; Deyoung K; Bhaskar S; Mumuney G; Coutinho A
Clin Lung Cancer; 2023 Jul; 24(5):429-436. PubMed ID: 37080814
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
15. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
[TBL] [Abstract][Full Text] [Related]
16. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
Go H; Kim DW; Kim D; Keam B; Kim TM; Lee SH; Heo DS; Bang YJ; Chung DH
J Thorac Oncol; 2013 Nov; 8(11):1445-50. PubMed ID: 24128715
[TBL] [Abstract][Full Text] [Related]
18. The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.
Fu S; Liang Y; Lin YB; Wang F; Huang MY; Zhang ZC; Wang J; Cen WJ; Shao JY
PLoS One; 2015; 10(4):e0124354. PubMed ID: 25905642
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Dalal AA; Guerin A; Mutebi A; Culver KW
J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]